retatrutide type 2 diabetes phase 2 trial hba1c Delivers Significant Hemoglobin A1C Reduction, Weight Loss in 3 🚨 BREAKING: Retatrutide Shows “Bariatric-Level”

In addition, the application for clinical registration of indications for nonalcoholic fatty liver/nonalcoholic steatohepatitis is in the final review stage

Originally approved by the FDA for the treatment of adult obesity in 2014, the drug received authorisation in 2020 for obesity in adolescents aged 12-17 years old (Mller, Blher, Tschp, DiMarchi)

Gut chemosensing: Interactions between gut endocrine cells and visceral afferents

Have difficulty managing hunger or overeating, despite efforts to maintain a healthy eating plan

Red Flags: Anemia, declining vitamin levels, or persistently elevated inflammation markers